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Background: Human autopsy research revealed that delayed vessel healing and sustained uncovered stent are the underlying mechanism of late 
stent thrombosis (LST).
Methods: Thirty mini pigs were divided into bare metal stent (BMS) group (n=15), SES group (n=15) and SES+atorvastatin pretreatment 
(SES+ator) group (50mg atorvastatin 12h before PCI and 20mg/day until sacrifice [n=15]). All animals were given BMS or SES implantation and 
optical coherence tomography (OCT) examination immediately after PCI, and at 7-day, 14-day and 28-day after stent implantation.
Results: Compared with BMS group, SES significantly delayed neointimal coverage and impaired endothelium function from the result of OCT, 
histology and SEM. However, the ratio of uncovered struts and sections with more than 30% uncovered struts in SES+ator group was significantly 
decreased at 7-day (31.3±5.7% vs. 56.8±5.7%, p<0.01; 45.7±11.8% vs. 84.9±4.3%, p<0.01, respectively) and 14-day (24.8±4.3% vs. 45.3±2.8%, 
p<0.01; 29.0±7.5% vs. 61.0±9.8, p<0.01, respectively) compared with the ration in SES group. Endothelial cell function on neointima was 
also improved by atorvastatin therapy in terms of less platelets adhesion at 7-day (213.9±58.0 vs. 111.46±10.6 per cm2, p=0.005), 14-day 
(199.7±10.9 vs. 81.1±16.1 per cm2, p=0.001), and 28-day (125.1±17.0 vs. 30.9±4.1 per cm2, p=0.007). Flow cytometry illustrated SES+ator 
group had more mobilized EPCs than SES group (0.21±0.02% vs. 0.11±0.03%, p=0.022). But OCT failed to identify whether neointima was 
completely re-endothelialization. And endothelialization score at 28-day showed better re-endothelialization at BMS and SES+ator group compared 
with SES group, through OCT revealed similarly complete neointima coverage in three groups at one month.
Conclusion: Atorvastatin pretreatment before PCI could accelerate the neointima coverage on SES and recover the endothelium function of the 
neointima which may help to reduce the risk of LST after drug-eluting stent implantation. 
